Advertisement
New Zealand markets closed
  • NZX 50

    12,349.47
    -46.80 (-0.38%)
     
  • NZD/USD

    0.5890
    +0.0001 (+0.01%)
     
  • NZD/EUR

    0.5417
    -0.0009 (-0.16%)
     
  • ALL ORDS

    8,153.40
    +59.10 (+0.73%)
     
  • ASX 200

    7,921.30
    +60.10 (+0.76%)
     
  • OIL

    76.44
    -1.84 (-2.35%)
     
  • GOLD

    2,385.70
    +32.20 (+1.37%)
     
  • NASDAQ

    19,023.66
    +193.07 (+1.03%)
     
  • FTSE

    8,285.71
    +99.36 (+1.21%)
     
  • Dow Jones

    40,589.34
    +654.27 (+1.64%)
     
  • DAX

    18,417.55
    +118.83 (+0.65%)
     
  • Hang Seng

    17,021.31
    +16.34 (+0.10%)
     
  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     
  • NZD/JPY

    90.5250
    -0.0680 (-0.08%)
     

Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?

Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?

Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.